You're contacting media contact of this press release

Title: Thailand Moves Clinical Research from Potential to Execution with Speed Key to Regional Competitiveness

Thailand, 26th Sep 2026 -  Thailand is moving from clinical research potential towards execution, as government, regulators, research institutions and industry advance concrete actions around three connected priorities: faster trial activation, stronger national coordination and earlier patient access to medical innovation.At the Policy Dialogue Forum 2026, co-convened by the Health Systems Research Institute (HSRI) and the Pharmaceutical Research & Manufacturers Association (PReMA), stakeholders agreed that Thailand’s clinical expertise, infrastructure and patient potential are already established. The challenge now is execution: moving faster and working as one system to strengthen Thailand’s regional competitiveness.  “Thailand has the foundational infrastructure and clinical expertise, but speed and national coordination remain our key competitiveness gaps,” said Dr. Alan , APAC, Head of Medical Affairs, GlaxoSmithKline (GSK), representing PReMA.Speed: Turning Action into Competitive AdvantageConcrete reforms are already underway. Dr. Supakit Sirilak, Executive Director, Health Systems Research Institute (HSRI), outlined the “Team Thailand” model to expand standards-compliant clinical research capacity from nine sites to around 40–50 hospitals nationwide. HSRI has also helped address a sponsor-funding bottleneck, with a regulatory process that would typically take around two years completed within six months.  The Thai FDA, represented by Pramote Akarapanon,Acting Expert on Development of Consumer Protection Systems of Health Products in Provincial and Local Administration, is shifting from regulator alone towards facilitator, including earlier consultation and work-sharing with HSRI and research ethics bodies to reduce duplicated r...

This press release is issued by King Newswire